First approved biosimilar from Biocon and Mylan’s joint portfolio in Europe
The European Commission has approved Mylan/Biocon’s co-developed biosimilar insulin glargine Semglee marketing authorization for people with diabetes after it got…
Pharmaceuticals, Biotechnology and Life Sciences
The European Commission has approved Mylan/Biocon’s co-developed biosimilar insulin glargine Semglee marketing authorization for people with diabetes after it got…
Glycotope has chosen Crown Bioscience to work together on immuno-oncology drug discovery pipeline, the subsidiary of Crown Bioscience Internation said…
Shield Therapeutics’s Feraccru can now be used as a treatment of all adults with iron deficiency (ID) as the company…
Novartis will sell its 36.5 percent stake in its consumer healthcare joint venture (JV) to GSK for $13.0 billion, it…
Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved…
Bristol-Myers Squibb said on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…
Portola will need to provide further clarification to the European Medicines Agency (EMA) for making betrixaban available for the prevention the VTE…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
Novartis could have the first therapy which could delay disability progression secondary progressive multiple sclerosis (SPMS) if it gets the…